Market Spotlight: Renal Disease
Market Spotlight: Renal Disease
$1,318.00
This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2018, there were approximately 738.0 million prevalent cases of chronic kidney disease (all stages) in adults aged 20 years and over worldwide. This figure is forecasted to increase to 819.5 million by 2027.
- Datamonitor Healthcare estimates that in 2018, there were 166.6 million cases (22.6%) in stage 1, 185.7 million cases (25.2%) in stage 2, 361.8 million cases (49.0%) in stage 3, 19.0 million cases (2.6%) in stage 4, and 4.8 million cases (0.4%) in stage 5.
- The approved drugs in the renal disease space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being intravenous, intramuscular, and subcutaneous formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for renal disease are in Phase I, with only one drug in the NDA/BLA stage.
- Therapies in the pipeline for renal disease focus on a wide variety of targets. The majority of these therapies are administered orally, with the remainder being intravenous, subcutaneous, hemoperfusion, intramuscular, and topical formulations.
- High-impact upcoming events for drugs in the renal disease space comprise topline Phase II trial results for suramin and ANG3777; topline Phase III trial results for Sibnayal, veverimer, recAP, and Jardiance; and an expected PDUFA date for Farxiga.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for renal disease have been in the early and mid-phases of development, with 56% of trials in Phase I–II, and 44% in Phase III–IV.
- The US has a substantial lead in the number of renal disease clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the renal disease space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for renal
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Treatment of acute kidney injury
11 Treatment of chronic kidney disease
13 EPIDEMIOLOGY
17 MARKETED DRUGS
19 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Veverimer for Renal Disease (December 8, 2020)
28 Veverimer for Renal Disease (October 20, 2020)
29 Farxiga for Renal Disease (August 30, 2020)
33 Veverimer for Renal Disease (August 21, 2020)
35 Farxiga for Renal Disease (July 28, 2020)
36 Veverimer for Renal Disease (July 14, 2020)
38 Farxiga for Renal Disease (March 30, 2020)
40 KEY UPCOMING EVENTS
41 KEY REGULATORY EVENTS
41 New To The Review Queue
41 Farxiga BTD Rests On Renal Outcomes Trial DAPA-CKD
41 FDA Clears Medtronic’s CRRT System For Pediatric Kidney Disease
42 LICENSING AND ASSET ACQUISITION DEALS
42 VTv Licenses Renal Disease Candidate To Anteris
42 Spectrum Licenses CKD Therapy To Unicycive
42 AstraZeneca Likes Sound Of Silence’s Science
42 Deals Shaping The Medical Industry, February 2020
44 REVENUE OPPORTUNITY
45 CLINICAL TRIAL LANDSCAPE
46 Sponsors by status
47 Sponsors by phase
48 Recent events
50 BIBLIOGRAPHY
50 Prescription information
51 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in prevalent cases of chronic kidney disease, 2018–27
19 Figure 2: Overview of pipeline drugs for renal disease in the US
20 Figure 3: Pipeline drugs for renal disease, by company
20 Figure 4: Pipeline drugs for renal disease, by drug type
21 Figure 5: Pipeline drugs for renal disease, by classification
33 Figure 6: Farxiga for Renal Disease (August 30, 2020): Phase III – DAPA-CKD
36 Figure 7: Farxiga for Renal Disease (July 28, 2020): Phase III – DAPA-CKD
40 Figure 8: Key upcoming events in renal disease
45 Figure 9: Clinical trials in renal disease
45 Figure 10: Top 10 drugs for clinical trials in renal disease
46 Figure 11: Top 10 companies for clinical trials in renal disease
46 Figure 12: Trial locations in renal disease
47 Figure 13: Renal disease trials status
48 Figure 14: Renal disease trials sponsors, by phase
LIST OF TABLES
14 Table 1: Prevalent cases of chronic kidney disease, 2018–27
16 Table 2: Prevalent cases of chronic kidney disease, by stage, 2018
18 Table 3: Marketed drugs for renal disease
22 Table 4: Pipeline drugs for renal disease in the US
27 Table 5: Veverimer for Renal Disease (December 8, 2020)
28 Table 6: Veverimer for Renal Disease (October 20, 2020)
30 Table 7: Farxiga for Renal Disease (August 30, 2020)
34 Table 8: Veverimer for Renal Disease (August 21, 2020)
35 Table 9: Farxiga for Renal Disease (July 28, 2020)
37 Table 10: Veverimer for Renal Disease (July 14, 2020)
38 Table 11: Farxiga for Renal Disease (March 30, 2020)
44 Table 12: Historical global sales, by drug ($m), 2015–19
44 Table 13: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Depression KOL Interview – US #1 
Sign up to the